Brain Tumor Implant Slashes Recurrence Risk by 93 Percent in New Trial

James Harrington MPH, Health & Biotech Journalist

✨ Why this is good news

Brain metastases are tumors that spread to the brain from other cancers, and they often grow back after surgery.

93 percent risk reduction.In a randomized trial, the GammaTile implant cut the risk of tumor regrowth or death by 93 percent compared to standard surgery alone. Before this, patients faced a high chance of recurrence within months after an operation.
One time permanent treatment.The implant delivers radiation directly to the tumor site over time, so patients do not need daily trips to the hospital for weeks of whole brain radiation. This spares healthy brain tissue and reduces side effects like memory loss.
FDA approved and now funded.GammaTile already received FDA clearance for both recurrent and newly diagnosed tumors, and a new $100 million investment will expand its availability. Before this funding, access was limited to select clinical sites.
Closes a critical care gap.Standard post-surgery care often leaves microscopic cancer cells behind, leading to regrowth. GammaTile fills the surgical cavity with radiation seeds that target those leftover cells immediately, changing the outlook for thousands of brain metastasis patients each year.

A surgically placed radiation implant called GammaTile has demonstrated a dramatic reduction in tumor regrowth and death among patients with operable brain metastases, according to final results from a randomized controlled trial. The findings, presented at the American Society of Clinical Oncology conference, mark a potential shift in how doctors approach post-surgical treatment for these common brain tumors.

The device, which received FDA clearance in 2018 for recurrent brain tumors and in 2020 for newly diagnosed malignant tumors, is designed to close a critical gap in standard care. Traditionally, patients wait several weeks after surgery before starting radiation therapy to allow the wound to heal. GammaTile is placed directly into the tumor cavity during surgery, delivering radiation immediately to the surrounding tissue. In the trial, this approach lowered the risk of tumor recurrence by 93 percent and the risk of death by 41 percent one year after treatment, compared with the current standard of surgery plus stereotactic radiation therapy. The two approaches showed equivalent safety profiles.

The company behind the implant, GT Medical, announced it has raised $100 million in a new funding round led by Viking Global, with participation from existing investors including MVM Partners, Gilde Healthcare, Evidity Health Capital, Medtech Venture Partners and FemHealth Ventures. CEO Per Langoe said the investment validates GammaTile’s potential to become a standard of care treatment for operable brain tumors. The funds will be used to expand access to the therapy and support ongoing studies, including a trial for patients with newly diagnosed glioblastomas, a more aggressive form of brain cancer.

The company previously raised $53 million in 2025, $45 million in 2023 and $16 million in 2020 to support the device. With the latest infusion of capital and strong clinical evidence, GammaTile is poised to reach more patients who may benefit from immediate, targeted radiation after surgery. Researchers are optimistic that this approach could improve outcomes and quality of life for thousands of people facing brain tumor surgery each year.

Brain Tumor Implant Glioblastoma Neurosurgery Recurrence Risk

This article is for informational purposes only and does not constitute medical advice. The information presented is based on published research and official announcements. Always consult a qualified healthcare professional before making any medical decisions.